Current treatments for Crohn’s disease prioritize early intervention with biological therapies, with several landmark trials demonstrating that starting biologic agents within the first years of diagnosis leads to superior patient outcomes. Although challenges remain, early use of biological treatments is increasingly supported in managing moderate to severe Crohn’s disease.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
D’Haens, G. et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 371, 660–667 (2008).
Colombel, J.-F. et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 390, 2779–2789 (2017).
D’Haens, G. R. et al. Vedolizumab treatment is more effective and safer in early versus late Crohn’s disease: final results of the Love-CD trial. United European Gastroenterol. J. 12, OP147 (2024).
Sands, B. E. et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet 399, 2200–2211 (2022).
Ponsioen, C. Y. et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol. Hepatol. 2, 785–792 (2017).
Stevens, T. W. et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: retrospective long-term follow-up of the LIR!C trial. Lancet Gastroenterol. Hepatol. 5, 900–907 (2020).
Schreiber, S. et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn’s disease. J. Crohns Colitis 7, 213–221 (2013).
Cozijnsen, M. A. et al. Top-down infliximab study in kids with Crohn’s disease (TISKids): an international multicentre randomised controlled trial. BMJ Open Gastroenterol. 3, e000123 (2016).
Noor, N. M. et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn’s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol. Hepatol. 9, 415–427 (2024).
Revés, J. et al. Early biological therapy within 12 months of diagnosis leads to higher transmural healing rates in Crohn’s disease. Clin. Gastroenterol. Hepatol. https://doi.org/10.1016/j.cgh.2024.07.034 (2024).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
D’Haens, G., Simsek, M. Early Crohn’s disease: can we change the disease course?. Nat Rev Gastroenterol Hepatol 22, 367–368 (2025). https://doi.org/10.1038/s41575-025-01072-w
Published:
Issue date:
DOI: https://doi.org/10.1038/s41575-025-01072-w
This article is cited by
-
The global burden of inflammatory bowel disease: from 2025 to 2045
Nature Reviews Gastroenterology & Hepatology (2025)
